ArticleBMJ open2021
Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study.
Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- [Construction of a predictive model for recompensation in patients with decompensated viral hepatitis-induced cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.Alimentary pharmacology & therapeutics · 2026Article
- Recompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges.Canadian journal of gastroenterology & hepatology · 2026Review
- The Correlation Between the Ratio of ALT to qHBsAg and the Recompensation of HBV-Related Cirrhosis Patients: A Retrospective Cohort Study Based on the Baveno VII Criteria.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Modelling the liver's regenerative capacity across different clinical conditions.JHEP reports : innovation in hepatology · 2025Article
- Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis.JHEP reports : innovation in hepatology · 2024Article
- Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Predicting diabetic kidney disease for type 2 diabetes mellitus by machine learning in the real world: a multicenter retrospective study.Frontiers in endocrinology · 2023Article
- Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy.Frontiers in cellular and infection microbiology · 2022Article
- Recompensation in Cirrhosis: Current Evidence and Future Directions.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to evaluate recompensation factors among patients with decompensated cirrhosis.
designA multicentre retrospective case-control study was conducted. Data were collected from and compared between groups of patients with recompensated and acute decompensated cirrhosis. Univariable and multivariable logistic regressions were used to select indicators associated with recompensation among patients with decompensated cirrhosis with different complications. A decision tree with 10-fold cross-validation was used to develop the model to identify patients with recompensation. We followed the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guideline for development and reporting of the new model.
settingThe study was conducted in six tertiary public hospitals in Chongqing, China.
participantsThis study included 3953 patients with decompensated cirrhosis.
resultsIn the total sample of included patients, there were 553 patients with recompensation and 3400 patients with acute decompensation, including 1158 patients with gastrointestinal bleeding, 1715 patients with a bacterial infection, 104 patients with hepatic encephalopathy and 423 patients with ascites. The most relevant indicator of recompensation selected by the decision tree model was albumin, with a threshold of 40 g/L. Total protein, haemoglobin, basophil percentage, alanine aminotransferase, neutrophil-to-lymphocyte ratio and diabetes were also selected to subsequently distinguish patients. The terminal nodes with a probability of recompensation was 0.89. The overall accuracy rate of the model was 0.92 (0.91-0.93), and it exhibited high specificity (86.9%) and sensitivity (92.6%).
conclusionsThe occurrence of recompensated cirrhosis could be identified by albumin, total protein, haemoglobin, basophil percentage, alanine aminotransferase, neutrophil-to-lymphocyte ratio and diabetes. These simple variables may help clinicians develop a treatment plan to encourage patients with decompensated cirrhosis to recompensate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.